Using PCR to personalise lung cancer treatment

Non-small cell lung cancer (NSCLC) is the most common form of lung cancer, and the ALK inhibitors have potential in targeted treatment of the disease. However, they are only effective in patients who have rearrangements in the anaplastic lymphoma receptor [...]